🔴 Alzamend Neuro is trading 5.7% down today as investors rotate away from small-cap biotech

Alzamend Neuro is trading at $1.16 (5.7% down) as recent macro-driven gains ease and investors rotate away from smaller biotech names.

• The move aligns with broader pressure across the biotechnology sector, with the SPDR S&P Biotech ETF (XBI) down approximately 2%.
• There is no fresh, company-specific news or regulatory catalyst reported today to directly explain the intraday decline.